Context Therapeutics (NASDAQ:CNTX) Stock Rating Lowered by Wall Street Zen

Context Therapeutics (NASDAQ:CNTX) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday.

Other equities analysts have also issued research reports about the company. HC Wainwright boosted their target price on Context Therapeutics from $4.00 to $5.00 and gave the stock a “buy” rating in a research report on Thursday, November 6th. JonesTrading initiated coverage on shares of Context Therapeutics in a report on Monday, December 22nd. They set a “buy” rating and a $7.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Context Therapeutics in a research report on Wednesday, January 21st. Lifesci Capital upgraded shares of Context Therapeutics to a “strong-buy” rating in a report on Monday, February 23rd. Finally, D. Boral Capital reiterated a “buy” rating and set a $9.00 target price on shares of Context Therapeutics in a research note on Thursday, November 6th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $6.00.

Context Therapeutics Price Performance

CNTX stock opened at $2.25 on Friday. Context Therapeutics has a 1-year low of $0.49 and a 1-year high of $2.85. The business has a fifty day moving average price of $1.90 and a 200-day moving average price of $1.35. The stock has a market capitalization of $206.73 million, a P/E ratio of -9.38 and a beta of 1.97.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Clear Harbor Asset Management LLC boosted its stake in shares of Context Therapeutics by 60.5% during the 3rd quarter. Clear Harbor Asset Management LLC now owns 92,804 shares of the company’s stock worth $90,000 after acquiring an additional 35,000 shares during the last quarter. Vanguard Group Inc. raised its holdings in Context Therapeutics by 4.0% in the 3rd quarter. Vanguard Group Inc. now owns 3,495,031 shares of the company’s stock worth $3,387,000 after purchasing an additional 134,449 shares during the period. Citadel Advisors LLC purchased a new position in Context Therapeutics during the third quarter valued at $100,000. Blue Owl Capital Holdings LP grew its holdings in Context Therapeutics by 0.3% during the fourth quarter. Blue Owl Capital Holdings LP now owns 7,432,906 shares of the company’s stock valued at $10,926,000 after purchasing an additional 25,000 shares during the period. Finally, Renaissance Technologies LLC grew its holdings in Context Therapeutics by 58.8% during the fourth quarter. Renaissance Technologies LLC now owns 508,329 shares of the company’s stock valued at $747,000 after purchasing an additional 188,202 shares during the period. 14.03% of the stock is currently owned by institutional investors.

Context Therapeutics Company Profile

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.